Nuclear Power Renaissance Underway in West Texas
When you think of innovative advancements in nuclear power technology, places like the Idaho National Laboratory and the Massachusetts Institute of Technology probably come to mind. But today, some very exciting nuclear power development work is being done in West Texas, specifically, at Abilene Christian University (ACU). That's where Natura Resources is working to construct a molten salt–cooled, liquid-fueled reactor (MSR). 'We are in the process of building, most likely, the country's first advanced nuclear reactor,' Doug Robison, founder and CEO of Natura Resources, said as a guest on The POWER Podcast. Natura has taken an iterative, milestone-based approach to advanced reactor development and deployment, focused on efficiency and performance. This started in 2020 when the company brought together ACU's NEXT Lab with Texas A&M University; the University of Texas, Austin; and the Georgia Institute of Technology to form the Natura Resources Research Alliance. In only four years, Natura and its partners developed a unique nuclear power system and successfully licensed the design. The U.S. Nuclear Regulatory Commission (NRC) issued a construction permit for deployment of the system at ACU last September. Called the MSR-1, ACU's unit will be a 1-MWth molten salt research reactor (MSRR). It is expected to provide valuable operational data to support Natura's 100-MWe systems. It will also serve as a 'world-class research tool' to train advanced reactor operators and educate students, the company said.
The technology is not new. It was actually proven decades ago. 'A molten salt reactor was built at Oak Ridge in the 1960s—the Molten Salt Reactor Experiment or the MSRE—and that reactor functioned for about five years, then was shelved in favor of solid-fuel or light-water reactors [LWRs] that we're all familiar with,' Robison explained. 'That was really a decision made because the customer in the 1960s was the Department of Defense, and Admiral Rickover was building a nuclear Navy, and they needed to enrich uranium to plutonium for warheads, and solid fuel reactors are more suited for those purposes,' Robison added. The coolant is one of the main differences between LWRs and MSRs. As the names imply, an LWR is cooled by water, while an MSR is cooled by molten salt. LWRs require thick pressure vessels and high-pressure piping to safely contain pressurized water, provide radiation shielding, and ensure long-term structural integrity. Today, there are no U.S. manufacturers with the capability to forge a large nuclear reactor vessel, so they must be sourced overseas. Notably, molten salt turns from a solid to a liquid at about 450C, but it doesn't turn to a gas until about 1,400C, which is above the melting point of stainless steel. 'What that means is you can never get to the point to where the salt flashes to a steam, so we operate at very, very high temperatures, which is a big advantage because the high process heat—from an efficiency standpoint and manufacturing standpoint—is incredibly valuable, but we operate at atmospheric pressure, because the salt never transfers into a gas. It goes from a solid to a liquid. And, if you were to have some kind of leak or release, once you drop below 450 degrees C, it immediately freezes back into a solid, so kind of picture candle wax, if you will. So, it's called 'walk-away safe' for that reason. You don't need a containment dome,' explained Robison. These factors significantly reduce the cost of MSR facilities compared to LWR plants. MSR reactor vessels, for example, can be manufactured by Teledyne Brown Engineering in Huntsville, Alabama, and perhaps elsewhere in the U.S. Robison said everything needed to construct an MSR can be made in America, and he expects much of it to be manufactured in Texas. 'Governor Abbott has said, 'We want Texas to capture this industry,' ' noted Robison. 'Houston, Texas refers to itself as the energy capital of the world. So, we've been working with the Greater Houston Partnership and the Houston Energy Transition Initiative [to answer the question] 'How does that manufacturing happen not just in the U.S., but how does it happen in Texas?' ' Liquid fuel also provides an advantage for MSRs versus the LWR's solid-fuel design. '[In] the solid-fueled reactor, you have the fuel inside the fuel rod. And under current technology, when you burn 3% to 5% of the fuel, then at that point, the rod begins to decay. That is your first level of containment, so you have to pull the rod. That now becomes 'spent nuclear fuel' and enters into the waste stream. You still have 95% to 97% of perfectly good fuel inside that fuel rod. And now the problem becomes: 'What do we do with this nuclear waste that's going to be around for 100,000 years?' ' In an MSR, the fuel is dissolved in the salt. 'What that means is we burn practically 100% of the fuel. We do not throw unspent nuclear fuel away, and so our efficiency goes way up. We do not generate the waste that you see with a light-water reactor,' said Robison. 'In fact, molten salt reactors can utilize current stockpiles of spent nuclear fuel that is sitting in storage at different nuclear reactors around the nation, and we can take that fuel, and re-utilize that as fuel for a molten salt reactor.'
Natura is not only focused on its ACU project, but it is also moving forward on commercial reactor projects. In February, the company announced the deployment of two advanced nuclear projects, which are also in Texas. These deployments, located in the Permian Basin and at Texas A&M University's RELLIS Campus, represent significant strides in addressing energy and water needs in the state. 'Our first was a deployment of a Natura commercial reactor in the Permian Basin, which is where I spent my career. We're partnering with a Texas produced-water consortium that was created by the legislature in 2021,' said Robison. 'Produced water' is the water brought to the surface during oil and gas extraction processes. It is a byproduct of hydrocarbon production and typically consists of formation water that was originally present in the underground reservoir, along with additional water introduced during extraction operations. It typically has a salinity that is three times that of seawater, but it can be double or triple that in some instances. In any case, it cannot be released on the surface and must currently be reinjected back into the formation, which can create additional problems. One of the things that can be done with the high process heat from an MSR is desalinization. 'So, we're going to be desalinating produced water and providing power—clean power—to the oil and gas industry for their operations in the Permian Basin,' said Robison. Meanwhile, at Texas A&M's RELLIS Campus, which is located about eight miles northwest of the university's main campus in College Station, Texas, a Natura MSR-100 reactor will be deployed. The initiative is part of a broader project known as 'The Energy Proving Ground,' which involves multiple nuclear reactor companies. The project aims to bring commercial-ready small modular reactors (SMRs) to the site, providing a reliable source of clean energy for the Electric Reliability Council of Texas (ERCOT). Robison believes the Stargate Project, a massive $500 billion initiative aimed at building advanced hyperscale data centers across the U.S. to power next-generation artificial intelligence (AI) models, could also present an opportunity for Natura. 'The very first deployment of Stargate is scheduled to be in Abilene, Texas. We can actually see the data center that's being constructed from the windows of our offices,' he said. 'We may see something happen there just given the proximity of what they're doing and what we're doing,' Robison envisaged. To hear the full interview with Robison, which contains more about the creation of Natura Resources, the selection of MSR technology for its design, its collaboration with ACU, the work done to license the reactor, and much more, listen to The POWER Podcast. Click on the SoundCloud player below to listen in your browser now or use the following links to reach the show page on your favorite podcast platform:
Apple Podcasts
Spotify
YouTube
YouTube Music
Amazon Music
iHeart
TuneIn
SoundCloud
The POWER Podcast · 184. Nuclear Power Renaissance Underway in West Texas
For more power podcasts, visit The POWER Podcast archives. —Aaron Larson is POWER's executive editor (@AaronL_Power, @POWERmagazine).
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
2 days ago
- Business Upturn
Novo Nordisk's subcutaneous and oral amycretin data published in The Lancet and presented at ADA 2025
By GlobeNewswire Published on June 21, 2025, 04:34 IST Subcutaneous amycretin phase 1b/2a data on the safety, tolerability and weight loss potential in people with overweight or obesity was published in The Lancet and presented at the American Diabetes Association (ADA) Scientific Sessions. 1,2 and presented at the American Diabetes Association (ADA) Scientific Sessions. Oral amycretin phase 1 data on the safety, tolerability and weight loss potential in people with overweight or obesity was also published in The Lancet. 3 Findings from the clinical trials indicate amycretin appeared tolerable with a safety profile consistent with other GLP-1 and amylin receptor agonists.1,2,3 Bagsværd, Denmark, 20 June 2025 – Novo Nordisk announces subcutaneous amycretin data being presented at the American Diabetes Association (ADA) 85 th Scientific Sessions in Chicago, US.1 Full results of two clinical trials evaluating the safety, tolerability and weight loss potential of subcutaneous and oral amycretin in people with overweight or obesity were published today in The Lancet medical journal.1,3 Amycretin is the first treatment that combines GLP-1 and amylin receptor agonism biology in a single molecule. The published and presented results from the once-weekly subcutaneous amycretin phase 1b/2a clinical trial showed that participants who received the treatment demonstrated significantly greater weight loss across the full range of doses investigated compared to placebo. Data being presented at ADA were collected from two parts of the trial; dose escalation (amycretin 60 mg), and dose escalation and maintenance (amycretin 20 mg, 5 mg and 1.25 mg).1,2 No plateauing in weight reduction was observed at the end of treatment (ranging from 20 to 36 weeks) with all tested doses, suggesting that a longer treatment duration may potentially contribute to additional weight loss.1,2 Estimated mean change in body weight from baseline with once-weekly subcutaneous (SC) amycretin: 1,2 * Dose Treatment % Weight change % Weight change duration (SC amycretin) (placebo) 60 mg 36 weeks -24.3% -1.1%20 mg** 36 weeks -22.0% 1.9%5 mg** 28 weeks -16.2% 2.3% 1.25 mg** 20 weeks -9.7% 2.0% * If all people adhered to treatment i.e. if all people followed the planned dosing schedule for the full trial period without any treatment discontinuations. ** Administered during a 12-week maintenance period. Once-weekly subcutaneous amycretin treatment escalated up to 60 mg appeared tolerable with a safety profile consistent with other GLP-1 and amylin receptor agonists.1,2 The number of treatment-emergent adverse events (TEAEs) increased in a dose-dependent manner, were mostly gastrointestinal, and were comparable to the rate and profile of TEAEs reported in early-phase studies of GLP-1 receptor, GLP-1 receptor/gastric inhibitory polypeptide (GIP) receptor, and amylin receptor agonists.1,2 The majority of TEAEs were mild to moderate in severity and resolved by the end of the study period.1,2 Of the participants who discontinued the trial, the majority were due to non-TEAE reasons.1,2 'As pioneers in obesity innovation, we are exploring multiple biological pathways to develop potentially transformative medicines that support the individual needs and preferences of people with obesity on their weight loss journey towards overall improved health,' said Martin Holst Lange, executive vice president for Development at Novo Nordisk . 'Amycretin is the first investigational treatment that combines GLP-1 and amylin receptor agonism biology in one molecule, working on distinct pathways and offering complementary effects on appetite control. The findings published and presented today are encouraging. We are excited to advance the clinical development of subcutaneous and oral amycretin into phase 3 to assess its potential as a therapeutic option for weight management.' The published once-daily oral amycretin phase 1 clinical trial data showed that participants receiving amycretin achieved greater weight loss compared to placebo.3 After 12 weeks of treatment with amycretin up to 50 mg and up to 2 times 50 mg, participants achieved a mean change in body weight of -10.4% and -13.1% respectively, compared to -1.2% with placebo.3 There were no apparent signs of weight loss plateauing within the 12 weeks of treatment in either of these amycretin-treated groups.3 Once-daily oral amycretin appeared to have an acceptable safety profile and was tolerable in all tested doses, with TEAEs in line with what was expected from targeting GLP-1 and amylin receptors.3 All reported TEAEs occurred in a dose-proportional manner, were mild to moderate in severity, and mostly gastrointestinal. No new safety signals appeared during the study.3 Based on the findings from the oral and subcutaneous amycretin trials, Novo Nordisk recently announced it will advance amycretin into phase 3 trials to further investigate the treatment as a potential new therapeutic option for weight management.4 About amycretin Amycretin is a unimolecular long-acting GLP-1 and amylin receptor agonist under development by Novo Nordisk, to provide an efficacious and convenient treatment for adults with overweight or obesity and for adults with type 2 diabetes. Amycretin is developed for subcutaneous and oral administration. Oral amycretin Phase 1 trial – The trial evaluated the single-ascending dose and multiple ascending doses for oral amycretin, up to 2 times 50 mg, in 144 people with overweight or obesity, with a total treatment duration of up to 12 weeks. Subcutaneous amycretin Phase 1b/2a trial – The trial investigated the safety, tolerability, pharmacokinetics, and proof-of-concept of once-weekly subcutaneous amycretin in 125 people with overweight or obesity. The trial was a combined single ascending dose, multiple ascending dose and dose-response trial investigating three different maintenance doses with a total treatment duration of up to 36 weeks. About Novo Nordisk Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 77,400 people in 80 countries and markets its products in around 170 countries. For more information, visit , Facebook , Instagram , X , LinkedIn and YouTube . Contacts for further information _______________________ References The Lancet: Dahl K, Toubro, S, Dey S, et al. Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: Results of a randomised, controlled, phase 1b/2a study. Dahl, K, et al. (2025). Amycretin, a Novel, Unimolecular GLP-1 and Amylin Receptor Agonist: Results of a Phase 1b/2a Clinical Trial. Poster 2002-LB. American Diabetes Association (ADA) 85th Scientific Sessions, Chicago, US, June 20 – 23, 2025. The Lancet: Gasiorek A, Heydorn A, Gabery S, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, randomised, placebo-controlled study. Novo Nordisk Company Announcement. Novo Nordisk to advance subcutaneous and oral amycretin for weight management into phase 3 clinical development. Available at: Attachment Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
2 days ago
Diabetes drug may cut migraine days in half with little weight loss: Study
Drugs in the same family as Ozempic and Wegovy are known for treating diabetes and helping with weight loss, but a small, early-stage study suggested they might also ease migraines -- even when there's no weight loss. The benefit appears to come from lowering pressure in the brain, Dr. Simone Braca, a neurologist at the University of Naples Federico II and lead author of the study, explained to ABC News. 'This study is very interesting in that the GLP 1s are hypothesized to lower brain pressure, which can then lower your chance of getting a headache or a migraine,' Braca said. The small, 12-week study tracked 26 adults with obesity who had chronic or frequent migraines. Published in Headache -- the official journal of the American Headache Society -- and presented at this week's European Academy of Neurology meeting in Finland, it tested liraglutide, a type of GLP-1 drug commonly used for diabetes and weight loss. After taking a daily 1.8 mg dose of liraglutide for three months -- the amount typically used to treat diabetes -- their average number of headache days per month dropped from 20 to about nine. Participants also reported less disability from migraines, with scores on a standard headache impact scale cut by more than half. Although some participants lost a small amount of weight, Braca said the few lost pounds were not meaningful enough to explain the improvement in migraines. Instead, Braca pointed to pressure from cerebrospinal fluid -- the liquid that surrounds and cushions the brain and spine. He said he believes that even slight buildups of this fluid can press on nearby veins and nerves in the brain, potentially triggering migraines. 'An increased pressure of the spinal fluid in the brain may be one of the mechanisms underlying migraine,' Braca said. 'And if we target this mechanism, this preliminary evidence suggests that it may be helpful for migraine.' Nearly half of patients reported at least a 50% reduction in headache days, according to the Headache paper. About 40% experienced mild side effects like nausea or constipation. None stopped taking the medication. With such promising results, Braca and his research team, led by Dr. Roberto De Simone, are already planning larger trials. Future studies will measure brain pressure more directly and explore whether other GLP 1 drugs might also offer the same relief but with fewer side effects. 'There are still a substantial portion of migraine patients that face an unmet need and that live with its burden,' he said. 'New drugs that could target other pathways, I think that could be reassuring to those patients and give them hope.' The study adds to growing evidence that GLP-1 drugs may have benefits beyond diabetes and weight loss. Researchers are already studying these medications for a range of other conditions, including reducing the risk of heart disease and stroke, easing symptoms of addiction and treating Alzheimer's disease.
Business Wire
2 days ago
- Business Wire
Verdiva Bio to Present New Data Highlighting Once-Weekly Potential of Its Investigational Oral Obesity Candidates at the ADA 85th Scientific Sessions
LONDON & SAN FRANCISCO--(BUSINESS WIRE)--Verdiva Bio Limited ('Verdiva' or 'the Company') a clinical-stage biopharmaceutical company focused on developing innovative therapies for obesity and cardiometabolic disorders, will present new data showcasing the once-weekly potential of Verdiva's investigational oral GLP-1RA and amylin analog peptide candidates at the American Diabetes Association (ADA) 85th Scientific Sessions. 'These presentations underscore the potential value of our compounds as the only once-weekly oral amylin and oral GLP-1 receptor agonist (RA) candidates known to be advancing into clinical studies," said Dr. Mohamed Eid, CMO, Verdiva Bio Share 'Our first data presentation as Verdiva Bio at the prestigious ADA meeting marks a key milestone for our team. These presentations underscore the potential value of our compounds as the only once-weekly oral amylin and oral GLP-1 receptor agonist (RA) candidates known to be advancing into clinical studies,' stated Dr. Mohamed Eid, CMO at Verdiva. 'The early clinical and preclinical data not only show the potential of these compounds individually, but also the additive effect they may have in combination, highlighting the flexibility of our modular portfolio approach. At Verdiva Bio, we are committed to developing convenient, patient-friendly and commercially scalable therapeutic options for obesity, cardiometabolic disorders and related complications. We're excited about the potential of our once-weekly oral peptide candidates to help address this global health challenge.' VRB-101: An investigational once-weekly oral GLP-1 analog This presentation highlights new clinical pharmacokinetic data for VRB-101, an investigational, once-weekly, cAMP-biased oral GLP-1RA formulated with Verdiva's clinically validated, proprietary oral delivery technology T2026. Phase 1 results demonstrated that oral VRB-101 achieved drug levels comparable to, or exceeding, those of currently available once-weekly injectable GLP-1RA therapies. These findings support continued investigation of VRB-101 as a potential once-weekly, scalable oral therapeutic option for both weight reduction and long-term weight maintenance, with the potential to exert potent weight reduction and may improve adherence via a more patient-friendly dosing regimen. Poster Presentation #069 Title: VRB-101 is a potent oral GLP-1 tablet with once-weekly dosing potential Date/Time: June 21, 2025, 12:30–1:30 p.m. Central Time Location: Poster Hall (Hall F1) 068, McCormick Place Convention Center VRB-103: Efficacy of novel once-weekly oral amylin analog as a monotherapy, and in combination with VRB-101 in vivo A second presentation will share novel preclinical data on VRB-103, an investigational potentially once-weekly oral amylin analog, tested alone and in combination with VRB-101. In preclinical models, the rationally designed peptide combination showed an additive effect on body weight reduction. Additionally, co-formulation of these peptides in a single tablet with T2026 maintained comparable plasma exposure for both compounds. These data support continued development of VRB-103 as both a monotherapy and in combination with VRB-101. Poster Presentation #068 Title: Efficacy of a novel oral amylin analog and the development of an oral GLP-1/amylin co-formulated tablet to produce high in vivo plasma exposures Date/Time: June 21, 2025, 12:30–1:30 p.m. Central Time Location: Poster Hall (Hall F1) 068, McCormick Place Convention Center About Verdiva Bio Verdiva Bio is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related complications achieve better outcomes via more patient-friendly therapeutic options. Verdiva's most advanced product candidate is VRB-101, an oral GLP-1 peptide in clinical development that has demonstrated potential efficacy in a phase 1 study in Australia, which also confirmed the viability of once-weekly dosing potential. The Company is also developing a portfolio of amylin molecules, including oral and subcutaneous agonists, and other undisclosed programs that offer the potential for enhanced efficacy and improved tolerability. The Verdiva team will harness the emerging science in gut-brain biology and leverage their history of successful drug development to advance novel therapeutic options aiming to transform the lives of millions living with obesity worldwide. For more information, please visit
